• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Genetics Market
    Genetics News
    Genetics Stocks
    • Genetics Market
    • Genetics News
    • Genetics Stocks

    GenomeFIRST Awarded $400K Grant to Bring Genomic Information into Patients' Care Plans

    Vivien Diniz
    Feb. 02, 2016 10:12AM PST
    Genetics Investing

    Geisinger Health System has been awarded a $400,000 grant from the Robert Wood Johnson Foundation (RWJF) to support GenomeFIRST Medicine, a unique program to help patients and providers understand and use genomic information in their health care.

    Geisinger Health System has been awarded a $400,000 grant from the Robert Wood Johnson Foundation (RWJF) to support GenomeFIRST Medicine, a unique program to help patients and providers understand and use genomic information in their health care.
    According to the press release:

    The GenomeFIRST Medicine program takes a comprehensive approach to care that includes genomic screening, interpretation and managing results — essentially changing health care by expanding providers’ ability to care for their patients before a problem arises. With support from the Robert Wood Johnson Foundation, Geisinger will pilot a scalable model for integrating genomic results into the everyday care of 300 Geisinger patients. The project will focus on the three most common genetic conditions in Geisinger’s GenomeFIRST program: Hereditary Breast and Ovarian Cancer Syndrome (HBOC), Lynch Syndrome, and Familial Hypercholesterolemia.

    Dr. Michael Murray, director of clinical genomics, Geisinger Genomic Medicine Institute commented:

    As we enter the era of precision health, we will increasingly use genetic information to identify health risk and then use preventive strategies to avoid disease. This program is building the infrastructure to do that. At Geisinger, we strongly believe that genome sequencing will become more and more integrated into routine care, and that GenomeFIRST Medicine will drive medicine toward early diagnoses and disease prevention for many of our patients.

    Click here to view the full press release. 

    genomic medicine
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES